1. Home
  2. LTBR vs CAPR Comparison

LTBR vs CAPR Comparison

Compare LTBR & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LTBR
  • CAPR
  • Stock Information
  • Founded
  • LTBR 1992
  • CAPR 2005
  • Country
  • LTBR United States
  • CAPR United States
  • Employees
  • LTBR N/A
  • CAPR N/A
  • Industry
  • LTBR Professional Services
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • LTBR Consumer Discretionary
  • CAPR Health Care
  • Exchange
  • LTBR Nasdaq
  • CAPR Nasdaq
  • Market Cap
  • LTBR 397.8M
  • CAPR 324.6M
  • IPO Year
  • LTBR N/A
  • CAPR N/A
  • Fundamental
  • Price
  • LTBR $15.13
  • CAPR $6.28
  • Analyst Decision
  • LTBR
  • CAPR Strong Buy
  • Analyst Count
  • LTBR 0
  • CAPR 8
  • Target Price
  • LTBR N/A
  • CAPR $24.75
  • AVG Volume (30 Days)
  • LTBR 1.5M
  • CAPR 1.4M
  • Earning Date
  • LTBR 08-11-2025
  • CAPR 08-11-2025
  • Dividend Yield
  • LTBR N/A
  • CAPR N/A
  • EPS Growth
  • LTBR N/A
  • CAPR N/A
  • EPS
  • LTBR N/A
  • CAPR N/A
  • Revenue
  • LTBR N/A
  • CAPR $13,392,150.00
  • Revenue This Year
  • LTBR N/A
  • CAPR N/A
  • Revenue Next Year
  • LTBR N/A
  • CAPR $6,061.53
  • P/E Ratio
  • LTBR N/A
  • CAPR N/A
  • Revenue Growth
  • LTBR N/A
  • CAPR N/A
  • 52 Week Low
  • LTBR $2.24
  • CAPR $3.98
  • 52 Week High
  • LTBR $18.80
  • CAPR $23.40
  • Technical
  • Relative Strength Index (RSI)
  • LTBR 52.17
  • CAPR 36.33
  • Support Level
  • LTBR $12.93
  • CAPR $6.17
  • Resistance Level
  • LTBR $16.19
  • CAPR $7.30
  • Average True Range (ATR)
  • LTBR 1.48
  • CAPR 0.43
  • MACD
  • LTBR -0.02
  • CAPR -0.11
  • Stochastic Oscillator
  • LTBR 37.48
  • CAPR 4.53

About LTBR Lightbridge Corporation

Lightbridge Corp is a United States-based nuclear fuel technology company. The business activity of the firm is functioned through one business segment, which is the development and commercialization of its nuclear fuel. The Nuclear Fuel Technology segment develops next generation nuclear fuel technology that increases the power output of commercial reactors and reduces the cost of generating electricity. Geographically, its operations are functioned through the region of Unites States.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: